NASDAQ:SHPG - Shire Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$179.20 As of 01/8/2019 01:00 AM ET

+0.30 (1.20%)

Get New Shire Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SHPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SHPG

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Shire in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $179.20.

Read Analyst Price Chart Description

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Shire. This rating has held steady since November 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
12/20/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
12/20/2018	William Blair	Downgrade	Outperform ➝ Market Perform		Low
12/11/2018	SunTrust Banks	Downgrade	Buy ➝ Hold		Low
12/4/2018	B. Riley	Reiterated Rating	Buy		High
10/23/2018	Royal Bank of Canada	Set Price Target	Buy	$195.00	Low
9/7/2018	Berenberg Bank	Downgrade	Buy ➝ Hold		Low
9/4/2018	Evercore ISI	Downgrade	Outperform ➝ Market Perform	$196.00	Low
9/4/2018	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform		Low
7/31/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
7/19/2018	Royal Bank of Canada	Set Price Target	Buy	$188.00	Low
5/11/2018	Kepler Capital Markets	Reiterated Rating	Buy ➝ Buy		Low
5/8/2018	Royal Bank of Canada	Reiterated Rating	Buy		Low
4/29/2018	BTIG Research	Reiterated Rating	Buy	$195.00	Low
4/22/2018	Royal Bank of Canada	Set Price Target	Buy	$186.00	Low
4/19/2018	B. Riley	Boost Price Target	Buy	$200.00	Low
4/16/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Medium
4/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
3/28/2018	Bank of America	Reiterated Rating	Buy		High
3/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	High
3/7/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
2/20/2018	SunTrust Banks	Lower Price Target	Buy	$190.00	Medium
2/20/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Neutral		Medium
2/19/2018	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$200.00 ➝ $150.00	High
2/16/2018	Royal Bank of Canada	Lower Price Target	Outperform	$181.00	Low
2/16/2018	B. Riley	Lower Price Target	Buy ➝ Buy	$201.00 ➝ $181.00	Low
2/15/2018	Royal Bank of Canada	Reiterated Rating	Buy		Low
2/14/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Medium
2/14/2018	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform		Medium
2/5/2018	Royal Bank of Canada	Set Price Target	Buy	$192.00	Low
2/5/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$236.00 ➝ $237.00	High
1/5/2018	Cowen	Set Price Target	Buy	$225.00	Low
1/3/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
1/3/2018	Piper Jaffray Companies	Reiterated Rating	Hold		Low
12/27/2017	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
12/20/2017	Liberum Capital	Reiterated Rating	Buy ➝ Hold		Medium
12/5/2017	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Medium
11/16/2017	Royal Bank of Canada	Reiterated Rating	Buy		N/A
11/16/2017	Cantor Fitzgerald	Set Price Target	Buy	$222.00	N/A
11/14/2017	Liberum Capital	Upgrade	Hold ➝ Buy		N/A
10/30/2017	(FBRC)	Reiterated Rating	Buy	$201.00	N/A
10/29/2017	Cowen	Set Price Target	Buy	$225.00	N/A
10/27/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$222.00	N/A
10/27/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$160.00	N/A
10/19/2017	(FBRC)	Initiated Coverage	Buy ➝ Buy	$201.00	N/A
10/11/2017	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$213.00	N/A
10/8/2017	Stifel Nicolaus	Reiterated Rating	Buy	$245.00	N/A
10/2/2017	Royal Bank of Canada	Reiterated Rating	Buy	$213.00	Low
9/14/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$222.00	Low
8/21/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$222.00	Low
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$196.00	Medium
8/15/2017	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
8/11/2017	Barclays	Downgrade	Overweight ➝ Equal Weight		Low
8/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	$216.00 ➝ $206.00	Low
8/4/2017	Royal Bank of Canada	Set Price Target	Buy	$213.00	Low
7/26/2017	Piper Jaffray Companies	Set Price Target	Hold	$159.00	Medium
7/17/2017	BTIG Research	Reiterated Rating	Buy	$242.00	Low
7/13/2017	Sanford C. Bernstein	Reiterated Rating	Market Perform	$210.00	Low
7/12/2017	Stifel Nicolaus	Reiterated Rating	Buy	$245.00	Low
7/11/2017	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Medium
7/1/2017	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Low
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$222.00	Low
6/9/2017	Stifel Nicolaus	Lower Price Target	Buy	$250.00 ➝ $245.00	Low
6/9/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$239.00 ➝ $216.00	Low
6/8/2017	Royal Bank of Canada	Set Price Target	Buy	$218.00	Low
6/1/2017	Liberum Capital	Downgrade	Buy ➝ Hold		Low
5/31/2017	Cowen	Reiterated Rating	Outperform	$325.00	Low
5/25/2017	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$209.22 ➝ $161.09	Low
5/18/2017	Royal Bank of Canada	Set Price Target	Buy	$221.00	Low
4/20/2017	Jefferies Financial Group	Set Price Target	Buy	$239.00	Low
4/18/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$221.00	Medium
4/17/2017	The Goldman Sachs Group	Boost Price Target	Overweight	$202.00 ➝ $214.00	Low
4/14/2017	The Goldman Sachs Group	Reiterated Rating	Conviction-Buy		N/A
3/21/2017	The Goldman Sachs Group	Reiterated Rating	Focus List		Low
3/18/2017	Jefferies Financial Group	Set Price Target	Buy	$239.00	Low
3/14/2017	Royal Bank of Canada	Reiterated Rating	Buy	$221.00	Low
3/9/2017	Liberum Capital	Initiated Coverage	Buy ➝ Buy		Low
3/7/2017	Barclays	Initiated Coverage	Overweight		N/A
2/17/2017	Jefferies Financial Group	Set Price Target	Buy	$248.00 ➝ $239.00	N/A
2/17/2017	Guggenheim	Reiterated Rating	Neutral		N/A
12/23/2016	BTIG Research	Reiterated Rating	Buy	$242.00	N/A
12/6/2016	UBS Group	Downgrade	Buy ➝ Hold		N/A
12/2/2016	Societe Generale	Initiated Coverage	Buy		N/A
11/14/2016	SVB Leerink	Set Price Target	Buy	$198.00	N/A
11/11/2016	Jefferies Financial Group	Set Price Target	Buy	$248.00	N/A
11/11/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$235.00	N/A
11/7/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
11/3/2016	Citigroup	Reiterated Rating	Buy		N/A
11/3/2016	Jefferies Financial Group	Reiterated Rating	Buy	$248.00	N/A
11/2/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A
11/1/2016	BTIG Research	Reiterated Rating	Buy	$242.00	N/A
10/24/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
10/23/2016	BNP Paribas	Reiterated Rating	Buy		N/A
10/17/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
10/16/2016	The Goldman Sachs Group	Reiterated Rating	Buy		N/A
10/8/2016	Shore Capital	Reiterated Rating	Buy		N/A
10/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
10/1/2016	SVB Leerink	Reiterated Rating	Buy		N/A
10/1/2016	Piper Jaffray Companies	Set Price Target	Hold	$201.00	N/A
9/28/2016	Shore Capital	Reiterated Rating	Buy		N/A
9/27/2016	Citigroup	Reiterated Rating	Buy		N/A
9/26/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
9/20/2016	Jefferies Financial Group	Reiterated Rating	Buy	$262.00	N/A
9/19/2016	Citigroup	Reiterated Rating	Buy		N/A
9/7/2016	Jefferies Financial Group	Reiterated Rating	Buy	$262.00	N/A
8/30/2016	Shore Capital	Reiterated Rating	Buy		N/A
8/17/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
8/13/2016	Shore Capital	Reiterated Rating	Buy		N/A
8/3/2016	Royal Bank of Canada	Reiterated Rating	Outperform		N/A
8/3/2016	Citigroup	Reiterated Rating	Buy		N/A
8/3/2016	SVB Leerink	Reiterated Rating	Outperform	$213.00 ➝ $231.00	N/A
8/3/2016	Guggenheim	Reiterated Rating	Neutral		N/A
8/1/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
7/26/2016	Shore Capital	Reiterated Rating	Buy		N/A
7/15/2016	Citigroup	Reiterated Rating	Buy		N/A
7/15/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$174.00	N/A
7/12/2016	SVB Leerink	Reiterated Rating	Buy	$213.00	N/A
7/12/2016	BTIG Research	Reiterated Rating	Buy	$230.00	N/A
7/7/2016	Shore Capital	Reiterated Rating	Buy		N/A
7/1/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
6/28/2016	The Goldman Sachs Group	Reiterated Rating	Buy		N/A

(Data available from 6/21/2016 forward)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Today's Range

Now: $179.20

$179.20

50 Day Range

MA: $179.20

$179.20

52 Week Range

Now: $179.20

$123.73

$182.47

Volume

N/A

Average Volume

2,212,143 shs

Market Capitalization

$54.71 billion

P/E Ratio

11.83

Dividend Yield

0.19%

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Shire?

The following equities research analysts have issued reports on Shire in the last twelve months:
View the latest analyst ratings for SHPG.

What is the current price target for Shire?

0 Wall Street analysts have set twelve-month price targets for Shire in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Shire in the next year.
View the latest price targets for SHPG.

What is the current consensus analyst rating for Shire?

Shire currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SHPG.

What other companies compete with Shire?

Other companies that are similar to Shire include Pfizer, Novartis, Eli Lilly and, AbbVie, Abbott Laboratories, Merck & Co., Inc., Novo Nordisk A/S, AstraZeneca, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, CSL, Zoetis, Bayer Aktiengesellschaft and Regeneron Pharmaceuticals.

How do I contact Shire's investor relations team?

Shire's physical mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company's listed phone number is 353-1609-6000 and its investor relations email address is [email protected] The official website for Shire is www.shire.com.